Prostanoids for the management of glaucoma

Authors: Arranz-Marquez, Esther; Teus, Miguel A

Source: Expert Opinion on Drug Safety, Volume 7, Number 6, November 2008 , pp. 801-808(8)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Background: Prostanoids are the newest pharmacologic group of ocular hypotensive drugs for clinical management of glaucoma. The group includes four chemical compounds structurally derived from naturally-occurring prostaglandin (PG) F_2α. Prostanoids have been divided into PG analogues (unoprostone, latanoprost and travoprost) and prostamides (bimatoprost) because of differences in molecular structures. The drugs share a novel mechanism of action that produces a potent ocular hypotensive effect and a novel local adverse effect of increased iridial pigmentation. Objective: To summarise the pharmacologic and clinical data regarding the effectiveness and safety of prostanoids in clinical glaucoma management. Methods: The review was supported by a literature search of peer-reviewed publications, based on medical information available in databases such as PubMed. Results/conclusion: The prostanoids began a treatment revolution not only because of their novel mechanism of action but also as a result of a new local side effect.

Keywords: bimatoprost; glaucoma; hypotensive drugs; IOP; latanoprost; PGF2α analogues; prostanoids; prostaglandin analogues; travoprost; unoprostone

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14740330802465474

Publication date: 2008-11-01

More about this publication?